What is the cost-effectiveness of using PCSK9 inhibitors for the secondary prevention of ASCVD?
The cost-effectiveness of using PCSK9 inhibitors for the secondary prevention of ASCVD has been evaluated in 7 published simulation models, as detailed in Section 7 (and Online Data Supplements 44 and 45). The reported incremental cost-effectiveness ratios range from $141700 to $450000 per added (QALY), with all but 1 model reporting low value (>$150000 per QALY added). All models agree that the value provided by PCSK9 inhibitors would be significantly improved by price reductions of 70% to 85% from the mid-2018 US list price of roughly $14000 a year.